An update on current and potential genetic insights and diagnosis of Alport syndrome

References

• Alport AC. Hereditary familial congenital haemorrhagic nephritis. Br Med J. 1927;1(3454):504–506.
   PubMedGoogle Scholar
• Hasstedt SJ, Atkin CL. X-linked inheritance of Alport syndrome: family P revisited. Am J Hum Genet. 1983;35:1241–1251.
   PubMed Web of Science ®Google Scholar
• Smith JM, Stablein DM, Munoz R, et al. Contributions of the transplant registry: the 2006 annual report of the north american pediatric renal trials and collaborative studies (NAPRTCS). Pediatr Transplant. 2007;11:366–373.
   Google Scholar
• Abraham AG, Betoko A, Fadrowski JJ, et al. Renin-angiotensin II-aldosterone system blockers and time to renal replacement therapy in children with CKD. Pediatr Nephrol. 2017;32:643–649.
   PubMed Web of Science ®Google Scholar
• System USRD. USRDS 2007 annual data report: atlas of end-stage renal disease in the United States; 2007.
   Google Scholar
• Kashtan CE, Ding J, Gregory M, et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol. 2013;28:5–11.
   PubMed Web of Science ®Google Scholar
• Omachi K, Miner JH. Alport syndrome therapeutics: ready for prime-time players. Trends Pharmacol Sci. 2019;40:803–806.
   PubMed Web of Science ®Google Scholar
• Torra R, Furlano M. New therapeutic options for Alport syndrome. Nephrol Dial Transplant. 2019;34(8):1272–1279.
   PubMed Web of Science ®Google Scholar
• Alport Syndrome Foundation. [cited 2020 Jun 24]. Available from: alportsyndrome.org.
   Google Scholar
• Alport Syndrome Treatments and Outcomes Registry. [cited 2020 Jun 24]. Available from: alportregistry.org.
   Google Scholar
• Gross O, Beirowski B, Koepke M-L, et al., Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int. 63(2): 438–446. 2003. .
   PubMed Web of Science ®Google Scholar
• Gross O, Licht C, Anders HJ, et al., Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 81(5): 494–501. 2012. .
   PubMed Web of Science ®Google Scholar
• Kashtan CE, Ding J, Garosi G, et al., Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 93(5): 1045–1051. 2018. .
   PubMed Web of Science ®Google Scholar
• Adam MP, Ardinger HH, Pagon RA, et al. GeneReviews. 1993. [cited 2020 Jun 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1207/
   Google Scholar
• Savige J, Gregory M, Gross O, et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol. 2013;24(3):364–375.
   PubMed Web of Science ®Google Scholar
• Fallerini C, Dosa L, Tita R, et al. Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet. 2014;86:252–257.
   PubMed Web of Science ®Google Scholar
• Morinière V, Dahan K, Hilbert P, et al. Improving mutation screening in familial hematuric nephropathies through next generation sequencing. J Am Soc Nephrol. 2014;25:2740–2751.
   PubMed Web of Science ®Google Scholar
• Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol. 2000;11(4):649–657.
   PubMed Web of Science ®Google Scholar
• Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. J Am Soc Nephrol. 2003;14:2603–2610.
   PubMed Web of Science ®Google Scholar
• Heidet L, Arrondel C, Forestier L, et al. Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol. 2001;12:97–106.
   PubMed Web of Science ®Google Scholar
• Storey H, Savige J, Sivakumar V, et al. COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. J Am Soc Nephrol. 2013;24:1945–1954.
   PubMed Web of Science ®Google Scholar
• Oka M, Nozu K, Kaito H, et al. Natural history of genetically proven autosomal recessive Alport syndrome. Pediatr Nephrol. 2014;29:1535–1544.
   PubMed Web of Science ®Google Scholar
• Pochet JM, Bobrie G, Landais P, et al. Renal prognosis in Alport’s and related syndromes: influence of the mode of inheritance. Nephrol Dial Transplant. 1989;4:1016–1021.
   PubMed Web of Science ®Google Scholar
• Deltas C, Savva I, Voskarides K, et al. Carriers of autosomal recessive alport syndrome with thin basement membrane nephropathy presenting as focal segmental glomerulosclerosis in later life. Nephron. 2015;130:271–280.
   PubMed Web of Science ®Google Scholar
• Kamiyoshi N, Nozu K, Fu XJ, et al. Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant alport syndrome. Clin J Am Soc Nephrol. 2016;11:1441–1449.
   PubMed Web of Science ®Google Scholar
• Marcocci E, Uliana V, Bruttini M, et al. Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome. Nephrol Dial Transplant. 2009;24:1464–1471.
   PubMed Web of Science ®Google Scholar
• Kashtan CE. Alport syndrome and the X chromosome: implications of a diagnosis of Alport syndrome in females. Nephrol Dial Transplant. 2007;22:1499–1505.
   PubMed Web of Science ®Google Scholar
• Savige J, Colville D, Rheault M, et al. Alport syndrome in women and girls. Clin J Am Soc Nephrol. 2016;11:1713–1720.
   PubMed Web of Science ®Google Scholar
• Savige J. Should we diagnose autosomal dominant alport syndrome when there is a pathogenic heterozygous. Kidney Int Rep. 2018;3:1239–1241.
   PubMed Web of Science ®Google Scholar
• Piccini M, Casari G, Zhou J, et al. Evidence for genetic heterogeneity in benign familial hematuria. Am J Nephrol. 1999;19(4):464–467.
   PubMed Web of Science ®Google Scholar
• Tiebosch AT, Frederik PM, van Breda Vriesman PJ, et al. Thin-basement-membrane nephropathy in adults with persistent hematuria. N Engl J Med. 1989;320:14–18.
   PubMed Web of Science ®Google Scholar
• Gast C, Pengelly RJ, Lyon M, et al. Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2016;31:961–970.
   PubMed Web of Science ®Google Scholar
• Xie J, Wu X, Ren H, et al. COL4A3 mutations cause focal segmental glomerulosclerosis. J Mol Cell Biol. 2015;7:184.
   PubMed Web of Science ®Google Scholar
• Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med. 2019;380:142–151.
   PubMedGoogle Scholar
• Yao T, Udwan K, John R, et al. Integration of genetic testing and pathology for the diagnosis of adults with FSGS. Clin J Am Soc Nephrol. 2019;14:213–223.
   PubMed Web of Science ®Google Scholar
• Bekheirnia MR, Reed B, Gregory MC, et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol. 2010;21:876–883.
   PubMed Web of Science ®Google Scholar
• Horinouchi T, Nozu K, Yamamura T, et al. Detection of splicing abnormalities and genotype-phenotype correlation in X-linked alport syndrome. J Am Soc Nephrol. 2018;29:2244–2254.
   PubMed Web of Science ®Google Scholar
• Hashimura Y, Nozu K, Kaito H, et al. Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain. Kidney Int. 2014;85:1208–1213.
   PubMed Web of Science ®Google Scholar
• Rheault MN, Kren SM, Hartich LA, et al. X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome. Nephrol Dial Transplant. 2010;25:764–769.
   PubMed Web of Science ®Google Scholar
• Grünfeld JP, Noël LH, Hafez S, et al. Renal prognosis in women with hereditary nephritis. Clin Nephrol. 1985;23:267–271.
   PubMed Web of Science ®Google Scholar
• Matthaiou A, Poulli T, Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systemic review. Clin Kidney J. ePub 2-12-20. doi:10.1093/ckj/sfz176
   Google Scholar
• Mencarelli MA, Heidet L, Storey H, et al. Evidence of digenic inheritance in Alport syndrome. J Med Genet. 2015;52:163–174.
   PubMed Web of Science ®Google Scholar
• Daga S, Fallerini C, Furini S, et al. Non-collagen genes role in digenic Alport syndrome. BMC Nephrol. 2019;20:70.
   PubMed Web of Science ®Google Scholar
• Voskarides K, Arsali M, Athanasiou Y, et al. Evidence that NPHS2-R229Q predisposes to proteinuria and renal failure in familial hematuria. Pediatr Nephrol. 2012;27:675–679.
   PubMed Web of Science ®Google Scholar
• Voskarides K, Papagregoriou G, Hadjipanagi D, et al. COL4A5 and LAMA5 variants co-inherited in familial hematuria: digenic inheritance or genetic modifier effect? BMC Nephrol. 2018;19:114.
   PubMed Web of Science ®Google Scholar
• Cosgrove D, Meehan DT, Grunkemeyer JA, et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev. 1996;10:2981–2992.
   PubMed Web of Science ®Google Scholar
• Miner JH, Sanes JR. Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): implications for Alport syndrome. J Cell Biol. 1996;135:1403–1413.
   PubMed Web of Science ®Google Scholar
• Rheault MN, Kren SM, Thielen BK, et al. Mouse model of X-linked Alport syndrome. J Am Soc Nephrol. 2004;15:1466–1474.
   PubMed Web of Science ®Google Scholar
• Temme J, Peters F, Lange K, et al. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int. 2012;81:779–783.
   PubMed Web of Science ®Google Scholar
• Gross O, Tönshoff B, Weber LT, et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int. 2020;97:1275–1286.
   PubMed Web of Science ®Google Scholar
• Boye E, Mollet G, Forestier L, et al. Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome. Am J Hum Genet. 1998;63:1329–1340.
   PubMed Web of Science ®Google Scholar
• Kashtan CE, Kleppel MM, Gubler MC. Immunohistologic findings in Alport syndrome. Contrib Nephrol. 1996;117:142–153.
   PubMedGoogle Scholar
• Kashtan C, Fish AJ, Kleppel M, et al. Nephritogenic antigen determinants in epidermal and renal basement membranes of kindreds with Alport-type familial nephritis. J Clin Invest. 1986;78:1035–1044.
   PubMed Web of Science ®Google Scholar
• Yoshioka K, Hino S, Takemura T, et al. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. Am J Pathol. 1994;144:986–996.
   PubMed Web of Science ®Google Scholar
• Peissel B, Geng L, Kalluri R, et al. Comparative distribution of the alpha 1(IV), alpha 5(IV), and alpha 6(IV) collagen chains in normal human adult and fetal tissues and in kidneys from X-linked Alport syndrome patients. J Clin Invest. 1995;96:1948–1957.
   PubMed Web of Science ®Google Scholar
• Meleg-Smith S, Magliato S, Cheles M, et al. X-linked Alport syndrome in females. Hum Pathol. 1998;29:404–408.
   PubMed Web of Science ®Google Scholar
• Kashtan CE, Atkin CL, Gregory MC, et al. Identification of variant Alport phenotypes using an Alport-specific antibody probe. Kidney Int. 1989;36:669–674.
   PubMed Web of Science ®Google Scholar
• Hoskovec JM, Bennett RL, Carey ME, et al. Projecting the supply and demand for certified genetic counselors: a workforce study. J Genet Couns. 2018;27:16–20.
   PubMed Web of Science ®Google Scholar
• Liptak A, Goodnough A Supreme Court to Hear Obamacare Appeal. New York TimesMarch 2, 2020.
   Google Scholar
• Merchant SN, Burgess BJ, Adams JC, et al. Temporal bone histopathology in alport syndrome. Laryngoscope. 2004;114:1609–1618.
   PubMed Web of Science ®Google Scholar
• Cosgrove D, Samuelson G, Meehan DT, et al. Ultrastructural, physiological, and molecular defects in the inner ear of a gene-knockout mouse model for autosomal Alport syndrome. Hear Res. 1998;121:84–98.
   PubMed Web of Science ®Google Scholar
• Harvey SJ, Mount R, Sado Y, et al. The inner ear of dogs with X-linked nephritis provides clues to the pathogenesis of hearing loss in X-linked Alport syndrome. Am J Pathol. 2001;159:1097–1104.
   PubMed Web of Science ®Google Scholar
• Zehnder AF, Adams JC, Santi PA, et al. Distribution of type IV collagen in the cochlea in Alport syndrome. Arch Otolaryngol Head Neck Surg. 2005;131:1007–1013.
   PubMedGoogle Scholar
• Glueckert R, Janecke A, Schrott-Fisher A, et al. Inner ear histopathological findings in Alport syndrome. Audiol Med. 2007;5:129–137.
   Google Scholar
• Cosgrove D, Kornak JM, Samuelson G. Expression of basement membrane type IV collagen chains during postnatal development in the murine cochlea. Hear Res. 1996;100:21–32.
   PubMed Web of Science ®Google Scholar
• Cosgrove D, Samuelson G, Pinnt J. Immunohistochemical localization of basement membrane collagens and associated proteins in the murine cochlea. Hear Res. 1996;97:54–65.
   PubMed Web of Science ®Google Scholar
• Meehan DT, Delimont D, Dufek B, et al. Endothelin-1 mediated induction of extracellular matrix genes in strial marginal cells underlies strial pathology in Alport mice. Hear Res. 2016;341:100–108.
   PubMed Web of Science ®Google Scholar
• Weinstock BA, Feldman DL, Fornoni A, et al. Clinical trial recommendations for potential Alport syndrome therapies. Kidney Int. 2020;97:1109–1116.
   PubMed Web of Science ®Google Scholar
• Kashtan CE, Gubler MC, Sisson-Ross S, et al. Chronology of renal scarring in males with Alport syndrome. Pediatr Nephrol. 1998;12:269–274.
   PubMed Web of Science ®Google Scholar
• Abrahamson DR, Hudson BG, Stroganova L, et al. Cellular origins of type IV collagen networks in developing glomeruli. J Am Soc Nephrol. 2009;20:1471–1479.
   PubMed Web of Science ®Google Scholar
• Lin X, Suh JH, Go G, et al. Feasibility of repairing glomerular basement membrane defects in Alport syndrome. J Am Soc Nephrol. 2014;25:687–692.
   PubMed Web of Science ®Google Scholar